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Regulated nucleo-cytoplasmic transport plays a major role in maintaining cellular homeostasis. CRM1 (chromosome
region maintenance 1 or exportin 1 or XPO 1) is responsible for the nucleo-cytoplasmic transport of more than
200 proteins, including most of the tumor suppressor proteins (TSP). CRM1 is overexpressed in pancreatic cancer,
osteosarcoma, glioma, cervical and hematological malignancies. This inspired the development of novel agents
that selectively inhibit nuclear exportins (SINEs). In this review we focus on the significance of CRM1 in carcinogenesis
and review the new development of SINE inhibitiors in hematological malignancies. Selinexor (KPT-330) as the
first-in-human SINE agent represents this novel class of anti-cancer agents.
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Regulated nucleo-cytoplasmic transport plays a major
role in maintaining cellular homeostasis. The mode of
transport across nuclear membrane depends primarily on
the size of the molecules. Small molecules undergo passive
diffusion through a protein complex called nuclear core
complex (NPC). However, the transport of macromole-
cules (>40Kda, “cargo”), requires an association between
transport receptors and the NPC [1-3].
The transport receptors belong to the karyopherin
Beta (Kap) family. Nineteen of them are present in the
human cells. These include importins, exportins and
bidirectional Kaps. The association between the NPC,
transport receptors and cargo proteins is controlled by a
Ran GTPase [4].
There are 7 export proteins or exportins in the Kap
family, such as CRM1, cas, exportin, etc. The CRM1
(chromosome region maintenance 1 or exportin 1 or
XPO 1) is responsible for the transport of more than
200 proteins, including most of the tumor suppressor
proteins (TSP). The relocation of TSPs to the cyto-
plasm results in their inactivation that leads to car-
cinogenesis [2].
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selectively inhibit nuclear exportins (SINEs) [4,5]. In this
review we focus on the significance of CRM1 in carcino-
genesis and review the new development of SINE inhibi-
tiors in hematological malignancies.CRM1/exportin 1/XPO1
CRM1 was first identified in early 90s. A mutation in
CRM1 gene was found to be affecting the chromosome
structure in the yeast schizosaccharomyces pombe. Hence
it was named as chromosome region maintenance [6].
However, its importance as an exportin was discovered
later [7]. The discovery of Leptomycin B, a natural
CRM1 inhibitor, aided the recognition of several CRM1
cargos [8]. Among all the exportins, CRM1 alone is
responsible for transporting most of the tumor suppres-
sors and growth regulators including p53, p21, FOXO,
PI3K/AKT, Wnt/ß-catenin, AP-1 and NF-kB, etc.
The structural model of the human CRM1 was studied
by X-ray crystallography modelling and electron micros-
copy [9]. CRM1 is a 120 kDa protein. It has 21 HEAT
repeats. Each HEAT repeat consists of two antiparallel
alpha helices termed A and B connected by an intraloop.
CRM1 comprises of a ring like structure, in which the A
helices form the outer convex and B helices the inner
concave [10]. The outer convex surface contains a
hydrophobic groove formed by HEAT repeats 11 and 12
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mations such as the B helix of H21. For example, in the
CRM1-cargo-RanGTP complex the H21B lies next to
the H21A. However, this conformation is not in the
CRM1-cargo complex without RanGTP [10].
Cargo proteins contain a leucine-rich nuclear export
signal (LR-NES) that is recognized by CRM1. The LR-
NES is a combined alpha-helical-extended peptide that
resides in a hydrophobic groove between the two
outer helices of CRM1 comprising of HEAT repeats
11 and 12 [1]. Now, more than 200 NES structures
have been identified [2].
Selective inhibitors of nuclear export (SINEs)
Leptomycin B (LMB) was the first CRM1 inhibitor
identified. Other natural inhibitors include ratjadone
C, anguinomycin, goniothalamin, along with the small
molecule inhibitors, N-azolylacrylates and CBS9106.
These inhibitors bind covalently to the cysteine residue
(Cys528) in the NES-binding groove of the human
XPO1. The binding prevents the loss of TSPs and
stops cell proliferation [11,12]. However, LMB could
not be considered as a therapeutic agent due to severe
dose limiting toxicities like anorexia, nausea and
vomiting [13].
In recent years, novel small molecule SINE compounds
that target CRM1 exportins have been developed, includ-
ing KPT-185, KPT-251, KPT−276, KPT-330 (selinexor)
and KPT-335 [3,14,15] (Figure 1). KPT-185 has been
extensively investigated in vitro. However, in vivo study of
this compound was limited by poor pharmacokinetics.
This led to the development of KPT-330, the first SINE to
reach clinical trials.
SINEs are now being explored in many clinical studies
on both solid and hematologic malignancies. In this
review, we discuss their potential as therapeutic agents
in blood cancers.Figure 1 The chemical structures of selective inhibitors of nuclear exp
trials. It is an oral small molecule inhibitor targeting CRM1/XPO1, the major nuSINEs in acute leukemias
The loss of tumor suppressors such as p53 has long
been associated with cellular immortalization and pro-
liferation. p53 promotes cell cycle arrest, apoptosis,
autophagy and differentiation [16].
In recent years, various gene mutations in FLT3 (Fms-
like tyrosine kinase 3), DNMT3A, NPM1 (nucleophosmin
1), and CEBPA (CCAAT enhancer-binding protein-α) have
been found to play important roles in leukemognenesis
[17-20]. NPM1 is a phosphoprotein that shuttles between
the nucleus and cytoplasm. It regulates the p53-ARF
pathway. The exon 12 mutation of the NPM1 gene has
been implicated in leukemogenesis. The mutation leads
to delocalization of NPM1 from the nucleolus to the
cytoplasm (NPMc+) [21].
In 2012, the effects of KPT-185 and KPT−276 on AML
cell lines and primary blasts were studied in vitro and
in vivo. NPMc + blasts were found to be most responsive
to SINEs (IC 50 = 100 nm). However, blasts with wild type
NPM1 were also found to be SINE sensitive. This
highlighted the role of other TSPs, especially p53 [22].
CRM1 inhibitors also induced blast differentiation. This
was gauged by measuring expression of proteins like
CEBPA that are involved in leukemogensis [20].
The prognostic significance of CRM1 was studied in 511
patients with newly diagnosed AML [23]. The viability of
AML cell lines was assessed after the addition of KPT-
185. It was found to induce apoptosis in p53 wild-type
cells but only marginally in p53 deficient ones. It was also
noted that patients with FLT3 or NPM1 mutations had
higher levels of CRM1. High CRM1 was found to be an
independent predictor of poor overall survival in AML
patients. The study also commented on the synergistic
approach of combining SINEs with Nutlin 3a, which is a
MDM2 (mouse double minute 2) inhibitor [23].
SINEs were also studied in a panel of 14 human T-
ALL cell lines, including Jurkat, and MOLT4 [24]. SINEsort (SINE). Selinexor (KPT-330) is the first-in-human SINE agent in clinical
clear-cytoplasmic exportin.
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rapid apoptosis in vitro. KPT −330 was studied in mice
bearing ALL or AML. KPT-330 demonstrated significant
survival benefit in these mice [24].
The effects of KPT-330 on Philadelphia chromosome
positive leukemia was studied in preclinical and clinical
specimens [25]. CRM1/XPO1 expression was markedly
increased in CML-BC, Ph(+) B-ALL as well as in Ph(−)
B-ALL. CRM1/XPO1 expression was increased mostly in
a TKI-sensitive manner in these cells. KPT-330 enhanced
apoptosis and decreased the clonogenic potential of
leukemic, but not normal, CD34(+) progenitors. The sur-
vival of BCR-ABL1(+) mice was found to be better with
KPT-330 treatment. Half of the KPT-330 treated mice
remained alive and, mostly, became BCR-ABL1 negative.
SINEs in chronic leukemias
The activities of SINEs were scrutinized in chronic
lymphoid leukemia (CLL) in a preclinical study [12].
SINEs curbed cell growth by forcing the nuclear reten-
tion of major TSPs like p53, IkB and FOXO. KPT-185
resulted in the down regulation of MCL-1 expression in
CLL cells. KPT-185 and KPT-251 were also examined in
stromal cells such as HS-5 [12]. SINEs increased overall
survival rate in the Emu-TCL1-SCID mouse model of
CLL with minimal toxicities. Therefore, CRM1/XPO1 is
a valid target in CLL with minimal effects on normal
cells. This favors further development of SINEs in CLL
and related hematologic malignancies [12].
KPT-330 (selinexor) was given to a 37 year-old male
patient with TKI resistant CML-AP as a compassionate
use since this patient has failed 9 prior therapies and
declined bone marrow transplantation [25]. The patient
received KPT-330 on a dose-escalation scale, but declined
further treatment after a week. This represents one of the
early experience in TKI-resistant CML patients.
SINEs in multiple myeloma (MM)
CRM1 is highly expressed and negatively correlates to
survival in MM. In a preclinical study, CRM1 inhibition
by SINE was explored in MM cells and in SCID mice.
Higher levels of CRM1 were associated with bortezomib
resistance, lytic bone disease and shorter survival. Blocking
CRM1 activity by SINEs induced apoptosis in isolated
MM cells and in those cultured in a simulated bone
marrow microenvironment [26]. KPT-330 and KPT-185
were found to directly block osteoclastogenesis and
bone resorption without adverse effects on osteoblasto-
genesis. This study also defined the role of CRM1 in
osteoclast formation. Both KPT-185 and KPT-330
inhibited NF-ĸB and NFATc1, thus preventing the for-
mation of a functional osteoclast [26]. This study also
noted a synergistic effect when SINEs were combined
with bortezomib [26].KPT-276 is known to downregulate the various onco-
genes, such as c-myc, cell division cycle 25 homolog A
(CDC25A) and bromodomain-containing protein 4
(BRD4). KPT-276 significantly reduced the viability of 12
human myeloma cell lines [27]. KPT-276 also enhanced
apoptosis in primary MM cells from patients. KPT-276
reduced monoclonal spikes and inhibited tumor growth
in a xenograft MM mouse model. A phase I clinical trial
of an analog of KPT-276 is ongoing in hematological
malignancies including MM.
SINEs in lymphoma
CRM1 is overexpressed in various lymphomas as well.
Lymphoma cell lines treated with SINEs had decreased
viability, irrespective of p53 function. Oral administration
of KPT-276 at 75 and 150 mg/kg resulted in significant
tumor reduction [28]. Subcutaneous injections of KPT-
251 (25 and 75 mg/kg) in mouse model resulted in signifi-
cant suppression of lymphoma growth; residual tumors
showed activation of the protein 73 pathway. This study
provided evidence that CRM1 can serve as a therapeutic
target in non-Hodgkin’s lymphoma (NHL) [28].
The effects of SINEs on mantle cell lymphoma (MCL)
were also studied [29,30]. Compared with normal cells,
MCL cells had higher XPO1 expression [29]. KPT-185
was found to enhance apoptosis of MCL cells through
increased nuclear p53 levels [29]. Oral administration of
KPT-276 significantly inhibited MCL growth in a mouse
model without severe toxicity [30]. KPT-276 increased
nuclear retention of CRM1.
A phase I trial of KPT-335 was done in 17 dogs with
lymphoma, mast cell tumor or osteosarcoma. KPT-335
was administered at an oral dose of 1.75 mg/kg twice
weekly. The common side effects of anorexia, weight
loss, vomiting and diarrhea were manageable with
supportive care [31].
KPT-330 (selinexor) was recently reported in a phase
I trial in 32 patients with heavily pretreated NHL [32].
The median age of the patients was 68; median prior
regimens: 3 (range 1–11). These patients received
KPT-330 across 8 dose levels (3 to 60 mg/m2).
Thrombocytopenia (20%) and neutropenia (20%) were
the dose-limiting grade 3 and 4 adverse events. Gastro-
intestinal toxicities were the most common adverse
events. Biomarker study from tumor biopsies confirmed
nuclear localization of tumor suppressor protein, c-myc
reduction, and apoptosis.
Conclusion and future directions
Currently, selinexor (KPT-330) is undergoing several
phase I and phase II clinical trials in both solid and
haematological malignancies (clinicaltrials.gov). Seli-
nexor represents a novel class of anti-cancer agents
[3,14,15,33].
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